Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Kala Pharmaceuticals (KALA) Looks Good: Stock Adds 6% in Session

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2020 Results - Earnings Call Transcript

Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Tops Revenue Estimates

Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Is  (KALA) Outperforming Other Medical Stocks This Year?

Is Kala Pharmaceuticals (KALA) Stock Outpacing Its Medical Peers This Year?

Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call Transcript

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Kala Pharmaceuticals (KALA) Is Up 2.56% in One Week: What You Should Know

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.

Kala Pharmaceuticals' Shares March Higher, Can It Continue?

Here's Why Momentum Investors Will Love Kala Pharmaceuticals (KALA)

DHT Holdings

Frontline

Sharps Compliance

Summit Therapeutics

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.

5 Stocks Up on Signs of Slowdown in Coronavirus Cases

Capcom Co., Ltd.

Unicharm Corp

Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.

3 Breakout Stocks for Explosive Returns

Kala Pharmaceuticals Looks To Keep Rally Going

Kala Pharmaceuticals achieved positive results from its phase 3 STRIDE-3 study using EYSUVIS to treat patients with dry eye disease.

Kala's Upcoming NDA Submission For EYSUVIS Is A Great Catalyst Opportunity

Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals, Inc. (KALA).

Kala Pharmaceuticals, Inc. (KALA) Shares March Higher, Can It Continue?

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

Kala Pharmaceuticals: Solid Progress

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2019 Results - Earnings Call Transcript

If STRIDE 3 trial succeeds, it would open an additional large target market in dry eye disease. An estimate of its pipeline value is provided.

Kala Pharmaceuticals: Rating Buy Ahead Of STRIDE 3 Data This Quarter

News for Kala Pharmaceuticals Stock (KALA)